Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

ExplainerUpdated 7 min read

MOTS-c for weight loss: what mouse and human studies show

MOTS-c prevented diet-induced obesity in mice, but no human trial has tested it for weight loss. What the mouse data show, what human blood studies found, and where it stands legally.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The short answer: MOTS-c has not been shown to cause weight loss in people. In mice on a high-fat diet, MOTS-c prevented diet-induced obesity and insulin resistance, and that single 2015 study is the source of most weight loss claims. [3] No published human trial has given MOTS-c and measured body weight or fat. The first randomized, placebo-controlled human trial we found was registered in 2026, is still recruiting, and measures insulin sensitivity rather than weight. [5]

This page walks through what the mouse studies found, what the human blood studies can and cannot tell you, and where MOTS-c stands legally. It does not give dosing, and no dosing for MOTS-c has been established in people.

Does MOTS-c help with weight loss?

In mice, yes. MOTS-c is a 16 amino acid peptide encoded in mitochondrial DNA. The 2015 study that named it found that its main target appears to be skeletal muscle, where it inhibits the folate cycle and activates AMPK, the cell's energy sensor. Treated mice were protected from both age-related and high-fat-diet-induced insulin resistance, and from diet-induced obesity. [3]

In people, the answer is unknown. Read the mouse result carefully: it shows that MOTS-c prevented weight gain in animals fed a fattening diet. That is a different question from whether it helps a person who already has obesity lose weight, and no human study has answered either one.

Our evidence grade for MOTS-c is animal only, the lowest grade that still has controlled experiments behind it. The obesity condition page ranks it below every approved GLP-1 medicine, each of which has large randomized trials with weight as the primary endpoint.

Does MOTS-c burn fat? What human studies measured

The human MOTS-c literature measures blood levels. It does not test treatment. Three findings come up most often.

  • Levels are higher, not lower, in obesity. A 2026 study compared 32 adults with obesity scheduled for bariatric surgery with 22 lean adults. Circulating MOTS-c was higher in the obesity group, rose sharply once insulin resistance passed a threshold, and did not change 6 months after surgery despite large drops in BMI. The authors suggest MOTS-c may be a compensatory response to metabolic stress. [6]
  • Levels track with abdominal and liver fat. In 125 adults without diabetes, plasma MOTS-c was positively associated with android (abdominal) fat and liver fat. [7]
  • A gene variant is linked to diabetes. A mitochondrial DNA variant that changes one amino acid in MOTS-c was associated with type 2 diabetes in Japanese men, and the variant peptide had weaker metabolic activity in cells. [8]

None of these studies gave anyone MOTS-c. A higher blood level in people with more fat does not show that adding more MOTS-c burns fat; it could equally be the body's response to insulin resistance. The insulin resistance page covers the treatments that have been tested in people.

Does MOTS-c give you energy?

The energy claim comes from a 2021 study. MOTS-c treatment improved running performance in young, middle-aged, and old mice, and treatment started late in life improved physical capacity and some healthspan measures. [4] The same paper sampled 10 healthy young men and found that exercise raised MOTS-c in their muscle and blood. [4]

So exercise increases MOTS-c in people, and MOTS-c increases exercise capacity in mice. What has not been shown is the step in between: that giving MOTS-c to a person improves energy, fatigue, or endurance. A 2023 review noted that no effective method of applying MOTS-c in the clinic has been developed. [9]

How long does MOTS-c take to work?

There is no human answer, because there are no human results. The mouse studies measured effects over weeks of treatment, and mouse timelines do not transfer to people. [3] [4] The registered phase 2a trial will randomize about 120 adults with prediabetes and overweight or obesity to MOTS-c or placebo for 12 weeks, with a change in an oral glucose tolerance test measure of insulin sensitivity as the primary outcome, plus safety through week 16. [5] Until that trial reports, any timeline or "results" claim is anecdotal.

MOTS-c results: why before and after claims do not count

Online MOTS-c results are usually self-reports from people who also changed diet, exercise, or other medicines. Without a control group, a report cannot separate the peptide from everything else. The only controlled results for MOTS-c are in animals. [3] [4]

MOTS-c nasal spray, injection, and supplement forms

Every MOTS-c treatment study we found used injection in mice, and the registered human trial uses subcutaneous injection. [3] [5] We found no published study of MOTS-c as a nasal spray, capsule, or oral supplement in people or animals, so there is no evidence on whether those forms deliver the peptide at all. Products sold in those forms are untested on that question.

Stacking MOTS-c with other peptides

Some people ask about combining MOTS-c with GLP-1 drugs or with retatrutide. No trial has tested MOTS-c with any other drug. The peptide stacks explainer covers why untested combinations carry unknown risk, and our comparisons of NAD+ vs MOTS-c and MOTS-c vs SS-31 set out what each compound's evidence does and does not show.

MOTS-c is not an FDA approved drug. At the July 23 to 24, 2026 meeting of FDA's Pharmacy Compounding Advisory Committee, FDA presented MOTS-c for the 503A bulks list. [10] FDA's drug center recommended against listing it, and the advisory committee voted in favor. [1] MOTS-c is not on the 503A bulks list, and FDA has proposed no rule. [11] On October 28, 2026, HHS released a draft enforcement discretion policy saying it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds single-ingredient MOTS-c by subcutaneous or intramuscular injection, on a patient-specific prescription, when all of the policy's conditions are met. [1] That is not an FDA approval or a 503A bulks listing, it is not binding, and HHS may revisit it; the notice was published in the Federal Register on October 30, 2026. [2] Our explainer on the draft HHS policy covers its conditions and what did not change. Products labeled for research use are not lawful for human use and are not verified for identity or purity.

For tested athletes, MOTS-c is prohibited at all times under WADA section S4.4, which names it as a metabolic modulator. [12]

The MOTS-c regulatory timeline tracks its regulatory status, the PCAC vote explainer covers what the committee meeting does and does not change, the MOTS-c cost page explains why advertised prices are not a comparable figure, and the state legal guide covers how state rules interact with federal compounding law.

What would change the evidence grade

Our grade for MOTS-c would move up only when a controlled human trial reports results. The registered phase 2a study is the first candidate: it is randomized, double-blind, and placebo-controlled, and it plans to report insulin sensitivity, HbA1c, fasting glucose, and anti-drug antibodies. [5] Even a positive result would answer a metabolic question, not a weight loss one, because body weight is not a listed outcome. A weight loss claim would need a trial with weight or fat mass as a primary endpoint, run long enough to see a difference, and reported with its side effects. We will update this page and the MOTS-c entity page when results are posted.

What has human evidence for weight loss

If weight loss is the goal, the medicines with randomized human evidence are the approved GLP-1 drugs, covered in the GLP-1 hub, and our peptides for weight loss ranking places MOTS-c in the context of every option we grade.

What's actually offered, and what that means for you

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [13] [14] [15]

What that means for you

  • A pharmacy that compounds MOTS-c relies on HHS's draft policy, which has strict conditions and which HHS can revisit, so it carries some regulatory risk. Compounding it outside those conditions, such as in a blend or by another route, has no federal basis. [1]
  • No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [16]
  • State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [17]
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [18] [19]

If you're going ahead anyway

Each step is on the MOTS-c page: check the pharmacy's license, what a legitimate prescription and consult look like, why this is safer than a research-use-only product, and questions to ask. These steps lower some risks. They do not make a compounded product safe, and FDA has not reviewed it. [16]

Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.

Frequently asked questions

Does MOTS-c help with weight loss?

Not in any published human trial. In mice on a high-fat diet, MOTS-c prevented diet-induced obesity and insulin resistance. No study has given MOTS-c to people and measured body weight; a randomized phase 2a trial registered in 2026 measures insulin sensitivity, not weight. [3] [5]

Does MOTS-c burn fat?

In mice it activated AMPK in skeletal muscle and prevented fat gain on a high-fat diet. In people, blood MOTS-c is higher in adults with obesity and tracks with abdominal and liver fat, which is an association, not evidence that taking it burns fat. [3] [6] [7]

Does MOTS-c give you energy?

Treated mice of young, middle, and old ages ran longer on a treadmill. In people, exercise raises MOTS-c in muscle and blood, but no human study has given MOTS-c and measured energy, fatigue, or exercise capacity. [4]

Is MOTS-c legal?

It is not FDA approved and not on the 503A bulks list. At FDA's July 2026 compounding advisory committee meeting, FDA's drug center recommended against listing it, and the committee voted in favor. Under a draft HHS policy released October 28, 2026, HHS says it does not intend to take enforcement action against licensed compounding of single-ingredient MOTS-c by subcutaneous or intramuscular injection on a patient-specific prescription, when all of the policy's conditions are met. That is not an FDA approval, and HHS may revisit it. It is prohibited for tested athletes under WADA section S4.4, which names it as a metabolic modulator. [1] [10] [11] [12]

Sources

Numbered citations in the article point to these primary sources. PubMed entries link to the indexed abstract. Evidence grades follow our methodology.

  1. [1]HHS: Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, with Appendix A and Appendix B (draft, October 2026)2026
  2. [2]Federal Register: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances; Notice of availability (HHS Office of the Secretary, FR Doc. 2026-22192, Docket No. HHS-OASH-2026-0496, published October 30, 2026)Federal Register, 2026
  3. [3]Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab 2015PubMed 25738459, 2015
  4. [4]Reynolds JC et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun 2021PubMed 33473109, 2021
  5. [5]ClinicalTrials.gov NCT07505745: phase 2a, randomized, double-blind, placebo-controlled study of MOTS-c for insulin sensitivity in adults with prediabetes and overweight or obesity (recruiting, 120 planned, 12 weeks)2026
  6. [6]Yoon SH et al. Systemic MOTS-c levels are increased in adults with obesity in association with metabolic dysregulation and remain unchanged after weight loss. J Clin Transl Endocrinol 2026PubMed 41551324, 2026
  7. [7]Sequeira IR et al. Plasma mitochondrial derived peptides MOTS-c and SHLP2 positively associate with android and liver fat in people without diabetes. Biochim Biophys Acta Gen Subj 2021PubMed 34419510, 2021
  8. [8]Zempo H et al. A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging (Albany NY) 2021PubMed 33468709, 2021
  9. [9]Zheng Y, Wei Z, Wang T. MOTS-c: a promising mitochondrial-derived peptide for therapeutic exploitation. Front Endocrinol 2023PubMed 36761202, 2023
  10. [10]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026

More from the blog